Examination of the rescue effects of folic acid on derangement of the tubo-ovarian ultrastructural architecture caused by methotrexate

Advances in Therapy

Volumn 23, Issue 5, 2006, Pages 772-777

  Bayram, Merih ^a,c   Ozogul, Candan ^a   Ercan, Z Sevim ^a   Dilekoz, Ergin ^a   Soyer, Canan ^b   Bayram, Orhan ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Kecioren Hospital Ankara   (Turkey)

^c NONE   (Turkey)

Author keywords

Electron microscopy; Folic acid; Methotrexate; Ultrastructure of fallopian tube

Indexed keywords

FOLIC ACID; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DESTRUCTION; CELL ULTRASTRUCTURE; CILIATED EPITHELIUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDICATION; ECTOPIC PREGNANCY; ELECTRON MICROSCOPY; FEMALE; NONHUMAN; OVARY DISEASE; RAT; UTERINE TUBE DISEASE; UTERINE TUBE MUCOSA;

EID: 33845680696     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850317     Document Type: Article

References (15)

1. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition, McGraw Hill Corp. 1996:1243-1247.
2. Bagshawe KD, Wilde CE. Infusion therapy for pelvic trophoblastic tumors. J Obstet Gynaecol Br Commonw. 1964;71565-570.
3. Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42:139-151.
4. Moreno JC, Velez A, Medina I, et al. Psoriasis, vasculitis and methotrexate. J Eur Acad Dermatol Venereol. 2003;17:466-468.
5. Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. Am J Obstet Gynecol. 1986;154:1299-1306.
6. Borgatta L, Burnhill MS, Tyson J, Leonhardt KK, Hausknecht RU, Haskell S. Early medical abortion with methotrexate and misoprostol. Obstet Gynecol. 2001;97:11-16.
7. Stoval TG, Ling FW, Gray LA, Carson SA, Buster JE. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstet Gynecol. 1991;77:749-753.
8. Ankum WM, Mol BWJ, Van der Veen F, Bossuyt PMM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril. 1996;65:1093-1096.
9. Stovall TG, Ling FW, Buster JE. Reproductive performance after methotrexate treatment of ectopic pregnancy. Am J Obstet Gynecol. 1990;162:1620-1624.
10. el-Lamie IK, Shehata NA, Kamel HA. Intramuscular methotrexate for tubal pregnancy. J Reprod Med. 2002;47:144-150.
11. Mol BWJ, Hajenius PJ, Engelsbel S, et al. Treatment of tubal pregnancy in The Netherlands: an economic comparison of systemic methotrexate administration and laparoscopic salpingostomy. Am J Obstet Gynecol. 1999;181:945-951.
12. Leeton J, Davison G. Nonsurgical management of unruptured tubal pregnancy with intra-amniotic methotrexate: preliminary report of two cases. Fertil Steril. 1988;50:167-169.
13. Hopwood D, Nyfors A. Liver ultrastructure in psoriatics related to methotrexate therapy. 2. Findings in bile ducts from 11 methotrexate treated psoriatics and 2 controls. Acta Pathol Microbiol Scand. 1977;85:801-811.
14. Harb JM, Werlin SL, Camitta BM, Oechler H, Kamin BA, Blank EL. Hepatic ultrastructure in leukemic children treated with methotrexate and 6-mercaptopurine. Am J Pediatr Hematol Oncol. 1983;5:323-331.
15. Jeynes BJ, Altmann GG. Light and scanning election microscopic observations of the effects of sublethal doses of methotrexate on the rat small intestine. Anat Rec. 1978;191:1-17.